Search Result

Results for "

platelet receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PDGFR (25) Platelet-activating Factor Receptor (PAFR) (35) 11β-HSD (2) 5-HT Receptor (13) Acyltransferase (1) Adenosine Receptor (2) Adenylate Cyclase (6) Adrenergic Receptor (6) Akt (3) AMPK (2) Amyloid-β (1) Angiotensin Receptor (2) Antibiotic (1) Apoptosis (28) Autophagy (16) Bacterial (9) Bcr-Abl (1) Biochemical Assay Reagents (1) c-Fms (2) c-Kit (5) c-Myc (1) Calcium Channel (9) Carnitine Palmitoyltransferase (CPT) (1) Caspase (2) CDK (1) COX (4) Cyclin G-associated Kinase (GAK) (2) Cytochrome P450 (3) Dengue Virus (2) Dopamine Receptor (6) Drug Derivative (1) Drug Isomer (1) Drug Metabolite (8) EGFR (1) Endogenous Metabolite (23) Environmental Pollutants (1) ERK (8) Estrogen Receptor/ERR (5) FAP (1) Fc Receptor (FcR) (1) Ferroptosis (3) FGFR (1) Flavivirus (2) FLT3 (2) FXR (4) G protein-coupled Bile Acid Receptor 1 (1) G Protein-coupled Receptor Kinase (GRK) (1) Glutathione Reductase (GR) (1) Glycoprotein VI (4) Histamine Receptor (3) Insulin Receptor (1) Integrin (38) Interleukin Related (1) Isotope-Labeled Compounds (22) JAK (5) Keap1-Nrf2 (3) LDLR (1) Leukotriene Receptor (4) Liposome (1) Lipoxygenase (2) LPL Receptor (1) MEK (2) Mitosis (2) MMP (1) Monoamine Transporter (6) mRNA (2) mTOR (1) Nucleoside Antimetabolite/Analog (8) Organoid (2) P-glycoprotein (1) P2X Receptor (3) P2Y Receptor (53) p38 MAPK (8) Parasite (1) PARP (3) PGE synthase (4) Phosphatase (1) Phosphodiesterase (PDE) (3) Phospholipase (3) PI3K (3) PKC (7) PPAR (2) Prostaglandin Receptor (45) Protease Activated Receptor (PAR) (25) Reference Standards (40) RET (1) Serotonin Transporter (2) SHP2 (2) Src (1) STAT (4) STING (2) Survivin (1) Syk (3) Target Protein Ligand-Linker Conjugates (1) Thrombin (4) Thrombopoietin Receptor (17) TNF Receptor (2) Transmembrane Glycoprotein (2) UGT (1) Vasopressin Receptor (4) VEGFR (7)
By Research Areas:	Cancer (75) Cardiovascular Disease (216) Endocrinology (19) Infection (14) Inflammation/Immunology (83) Metabolic Disease (22) Neurological Disease (29)
Oligonucleotides:	Nucleotide Analogs (5) Aptamers (3) Phospholipids (2) mRNA (2) Adenine Nucleotide (5)

353

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

GMP Molecules

Targets Recommended: Platelet-activating Factor Receptor (PAFR) PDGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10064

Ticagrelor 10+ Cited Publications AZD6140; AR-C 126532XX	P2Y Receptor	Cardiovascular Disease Cancer
Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.

HY-P0078

TRAP-6 5+ Cited Publications PAR-1 agonist peptide; Thrombin receptor Activator Peptide 6	Protease Activated Receptor (PAR)	Inflammation/Immunology
TRAP-6 (PAR-1 agonist peptide), a peptide fragment, is a selective *protease activating receptor* 1 (PAR1)** agonist. TRAP-6 activates human platelets via the thrombin receptor. TRAP-6 shows no activity at PAR4 .

HY-B0686

Eptifibatide Maximum Cited Publications 9 Publications Verification	Integrin	Cardiovascular Disease
Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity .

HY-112486

TA-316 Megakaryocytes/platelets inducing agent	Cyclin G-associated Kinase (GAK)	Cardiovascular Disease
TA-3166 (Megakaryocytes/platelets inducing agent) is a novel chemically synthesized c-MPL agonist (CMA) and thrombopoietin (TPO) receptor agonist. TA-316 enhances ex vivo platelet generation from human-induced pluripotent stem (iPS) cells .

HY-13965

Parmodulin 2 5 Publications Verification ML161	Protease Activated Receptor (PAR)	Cardiovascular Disease
Parmodulin 2 (ML161) is an allosteric inhibitor of *protease-activated receptor* 1 (PAR1) with an IC₅₀** of 0.26 μM . Parmodulin 2 is a potent and non-competitive inhibitor of SFLLRN-induced P-selectin expression leading to inhibition of platelet aggregation in vitro and platelet thrombus formation in vivo .

HY-108660

PSB-0739 1 Publications Verification	P2Y Receptor	Cardiovascular Disease
PSB-0739 is a high-affinity potent, competitive, nonselective platelet P2Y₁₂ receptor antagonist with a K_i values of 24.9 nM. The P2Y₁₂ receptor plays a crucial role in platelet aggregation. Antithrombotic effect .

HY-15284

Prasugrel 1 Publications Verification PCR 4099	P2Y Receptor	Cardiovascular Disease
Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-108912

RO1138452 CAY10441	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
RO1138452 is a potent and selective IP (prostacyclin) *receptor* antagonist. RO1138452 displays high affinity for IP receptors. In human platelets, pK_i is 9.3±0.1; in a recombinant IP receptor system, pK_i is 8.7±0.06.

HY-101957

AG 1295 4 Publications Verification	PDGFR	Cardiovascular Disease
AG 1295 is a selective platelet-derived growth factor receptor (PDGFR) tyrosine-kinase inhibitor. AG1295 abolishes autophosphorylation of the PDGFR whereas not affects the autophosphorylation of the EGF receptor .

HY-P0074

GPRP 3 Publications Verification Gly-Pro-Arg-Pro; Pefa 6003	Thrombin	Cardiovascular Disease
GPRP (Gly-Pro-Arg-Pro; Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein Ⅱb/IIIa complex (glycoprotein IIb/IIIa receptor) . GPRP increases the level of free thrombin in activated platelet-rich plasma by reducing the adsorption of thrombin onto fibrin. GPRP inhibits platelet aggregation and prolongs the thrombin-initiated clotting time in plasma. GPRP is applicable for research related to thrombosis and thrombotic diseases .

HY-15284A

Prasugrel hydrochloride 1 Publications Verification PCR 4099 hydrochloride	P2Y Receptor	Cardiovascular Disease
Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-18200

Atopaxar E5555; ER-172594-00	Protease Activated Receptor (PAR) JAK Apoptosis	Cardiovascular Disease Cancer
Atopaxar (E5555) is a potent, orally active, selective and reversible thrombin receptor *protease-activated receptor-1 (PAR-1)* antagonist. Atopaxar, an antiplatelet agent, interferes with platelet signaling. Atopaxar can be used for the research of atherothrombotic disease .

HY-P1741

Fibrinogen-Binding Peptide 1 Publications Verification	Thrombin	Cardiovascular Disease
Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin .

HY-107867

(±)-Clopidogrel bisulfate	P2Y Receptor	Cardiovascular Disease Inflammation/Immunology
(±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .

HY-13463A

Avatrombopag maleate 5 Publications Verification AKR-501 maleate; E5501 maleate; YM477 maleate	Thrombopoietin Receptor Cytochrome P450 ERK STAT	Inflammation/Immunology Cancer
Avatrombopag (AKR-501) maleate is an orally active, non-peptide thrombopoietin receptor (TPO receptor) agonist (EC₅₀: 3.3 nM). Avatrombopag maleate mimics the biological activity of TPO. Avatrombopag maleate increases platelet production by activating intracellular signaling systems and promotes the production of platelets and megakaryocytes from hematopoietic precursor cells. Avatrombopag maleate is a substrate for cytochrome P450 (CYP) 2C9 and CYP3A .

HY-112322

Carbacyclin 1 Publications Verification Carbaprostacyclin; Carba-PGI2	PPAR Prostaglandin Receptor Carnitine Palmitoyltransferase (CPT)	Cardiovascular Disease Metabolic Disease
Carbacyclin is a PGI2 analogue, acts as a prostacyclin (PGI2) receptor agonist and vasodilator, and potently inhibits platelet aggregation.

HY-123669

R-138727	P2Y Receptor Drug Metabolite	Cardiovascular Disease
R-138727, the major active metabolite of Prasugrel (HY-15284), is a highly potent and selective irreversible antagonist of the P2Y12 receptor, with an IC₅₀ of 2.5 μM. R-138727 covalently binds to the P2Y12 receptor on the platelet surface, blocking adenosine diphosphate-mediated platelet activation and aggregation. R-138727 can be used to study stroke, cerebral infarction and neurological deficits.

HY-B0686B

Eptifibatide acetate Maximum Cited Publications 9 Publications Verification	Integrin	Cardiovascular Disease
Eptifibatide acetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity .

HY-144390

(S)-S007-1558 1 Publications Verification GPVI antagonist 1	Glycoprotein VI	Cardiovascular Disease
(S)-S007-1558 (compound 5) is a glycoprotein VI (GPVI) platelet receptor antagonist. (S)-S007-1558 inhibits collagen-induced platelet aggregation with an IC₅₀ of 25.3 μM .

HY-108627

DMPQ dihydrochloride	PDGFR	Others
DMPQ dihydrochloride is a potent and selective inhibitor of human platelet-derived growth factor receptor β (PDGFRβ) with an IC₅₀ of 80 nM .

HY-14851

MRE 0094 Sonedenoson	Adenosine Receptor	Inflammation/Immunology
MRE 0094 (Sonedenoson) is a selective activator for *adenosine receptor* A2A, with a K_i** of 490 nM. MRE 0094 exhibits anti-platelet and anti-inflammatory activities .

HY-15284S2

Prasugrel-d4 PCR 4099-d₄	P2Y Receptor	Cardiovascular Disease
Prasugrel-d₄ is the deuterium labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-114745

MoTP	Platelet-activating Factor Receptor (PAFR)	Cancer
MoTP is a specific **platelet activating factor receptor** antagonist and can induce melanocyte ablation. MoTP can be used for the research of cancer.

HY-164580

RO3244794	Prostaglandin Receptor	Neurological Disease Inflammation/Immunology
RO3244794 is a potent and selective IP (prostacyclin) receptor antagonist, with a pK_i of 7.7 and 6.9 in human platelet and recombinant IP receptor system, respectively. RO3244794 exhibits analgesic and anti-inflammatory potential .

HY-W700638A

Benafentrine maleate AH 21-132	Platelet-activating Factor Receptor (PAFR) Phosphodiesterase (PDE)	Cancer
Benafentrine maleate is a platelet activating factor receptor (PAFR) antagonist and a PDE 4 inhibitor .

HY-P1741A

Fibrinogen-Binding Peptide TFA 1 Publications Verification	Integrin	Cardiovascular Disease
Fibrinogen-Binding Peptide TFA (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide TFA binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin .

HY-136501

MRS2395	P2Y Receptor	Cardiovascular Disease
MRS2395, an dipivaloyl derivative, is a potent P2Y12 receptor antagonist. MRS2395 inhibits ADP-induced platelet activation with a K_i of 3.6 μM. MRS2395 inhibits cAMP induced by ADP in rat platelets in the presence of PGE1 with an IC₅₀ of 7 µM. MRS2395 enhances platelet dense granule release in response to TRAP-6 .

HY-147079A

Egaptivon pegol sodium ARC 1779 sodium	Integrin	Cardiovascular Disease
Egaptivon pegol sodium is an aptamer, which blocks binding of the von Willebrand Factor (VWF) to platelet GPIb receptors. Egaptivon pegol sodium has anti-thrombotic efficacy.

HY-18200B

Atopaxar hydrobromide E5555 hydrobromide; ER 172594-06	Protease Activated Receptor (PAR) JAK Apoptosis	Cardiovascular Disease Cancer
Atopaxar (E5555) hydrobromide is a potent, orally active, selective and reversible thrombin receptor *protease-activated receptor-1 (PAR-1)* antagonist. Atopaxar hydrobromide, an antiplatelet agent, interferes with platelet signaling. Atopaxar hydrobromide can be used for the research of atherothrombotic disease .

HY-106899

MK 287	Platelet-activating Factor Receptor (PAFR)	Cardiovascular Disease
MK 287 is a potent, selective and orally active antagonist of **platelet-activating factor receptor (PAFR*). MK 287 can inhibit [3H]C18-PAF binding to human platelet, polymorphonuclear leukocyte (PMN) and lung membranes with K1 values of 6.1, 3.2, and 5.49 nM, respectively. MK 287 can inhibit PAF-induced aggregation of platelets* in plasma or gel-filtered platelets and elastase release from PMNs with ED₅₀ values of 56, 1.5 and 4.4 nM. MK 287 can be used for the research of cardiovascular disease, such as thrombosis .

HY-165587

BM-573	Prostaglandin Receptor	Cardiovascular Disease
BM-573 is an orally active dual thromboxane A₂ (TXA₂) modulator with an IC₅₀ of 1.3 nM. BM-573 possesses both thromboxane synthase (TxAS) inhibition and thromboxane receptor (TP) antagonistic effects. BM-573 can completely inhibit platelet aggregation induced by Arachidonic acid (HY-109590) or U-46619 (TXA₂ analogues). BM-573 completely blocks the generation of TXB₂ (the stable metabolite of TXA₂) in human platelets and does not inhibit cyclooxygenase (COX-1/COX-2), thus avoiding interference with other prostaglandin synthesis. BM-573 has an inhibitory effect on U-46619-induced contractions in rat gastric fundus smooth muscle (ED₅₀ = 4.2 μM), but has no effect on contractions caused by PGE₂, PGF₂α, or PGI₂. BM-573 can be used in the study of atherosclerosis, myocardial infarction, pulmonary hypertension and shock .

HY-B0686A

Eptifibatide monoacetate	Integrin	Cardiovascular Disease
Eptifibatide monoacetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity .

HY-117177

XV459	Integrin	Cardiovascular Disease
XV459 is an orally active platelet GPIIb/IIIa receptor antagonist. XV459 blocks all agonist induced platelet aggregation by binding to platelet GPIIb/IIIa receptors. XV459 can significantly prolong occlusion time, reduce thrombus weight, and maintain blood flow. XV459 can be used for anti thrombotic research .

HY-U00040

PAF-AN-1	Platelet-activating Factor Receptor (PAFR)	Cardiovascular Disease Inflammation/Immunology
PAF-AN-1 is a platelet activating factor receptor (PAF) antagonist.

HY-101731

CP-96021 hydrochloride	Leukotriene Receptor	Inflammation/Immunology
CP-96021 hydrochloride is a balanced, combined, potent and orally active *leukotriene D4 (LTD4)/platelet* activating factor (PAF)** receptor antagonist with K_i values of 34 nM and 37 nM, respectively .

HY-120694

ML165 RUC-2	Integrin	Cardiovascular Disease
ML165 (RUC-2) is an aIIbb3 receptor antagonist. ML165 has orthosteric inhibition effect at the RGD binding domain. ML165 inhibits platelet adhesion to fibrinogen, and inhibits platelet aggregation (IC₅₀: 96 nM) .

HY-149462

KN1022	PDGFR	Cardiovascular Disease
KN1022 an inhibitor of phosphorylation of platelet-derived growth factor receptor (PDGFR) with IC₅₀ of 0.24 μM .

HY-N12995

α-Bulnesene	Platelet-activating Factor Receptor (PAFR)	Cardiovascular Disease
α-Bulnesene is a novel PAF receptor antagonist with the IC₅₀ of 17.62 μM. α-Bulnesene can be isolated from Pogostemon cablin. α-Bulnesene shows inhibitory effect on platelet-activating factor and arachidonic acid induced rabbit platelet aggregation .

HY-108633

BYK 49187	PARP	Cancer
AR-C66096 (FPL 66096) tetrasodium is a selective platelet P2Y_T receptor antagonist. AR-C66096 tetrasodium effectively blocks ADP-induced platelet aggregation. AR-C66096 tetrasodium can be used in the research of thromboembolism .

HY-10307

Roxifiban	Integrin	Cardiovascular Disease
Roxifiban is a **platelet glycoprotein (GP) IIb/IIIa receptor** inhibitor that can be used in the study of angina .

HY-103136

R-96544	5-HT Receptor	Cardiovascular Disease
R-96544 is an orally active 5-HT_2A receptor antagonist. R-96544 can inhibit platelet aggregation in vitro .

HY-10307A

Roxifiban acetate DMP 754	Integrin	Cardiovascular Disease
Roxifiban (acetate) is the acetate form of Roxifiban (HY-10307). Roxifiban (acetate) is a **platelet glycoprotein (GP) IIb/IIIa receptor** inhibitor that can be used in research related to angina .

HY-123206

R-96544 free base	5-HT Receptor	Inflammation/Immunology
R-96544 (free base) is a potent, selective and competitive 5-HT2 receptor antagonist. R-96544 (free base) inhibits platelet aggregation induced by serotonin, and inhibits 5-HT2A receptor-mediated contraction of guinea pig trachea .

HY-10315

Elarofiban RWJ-53308	Integrin	Cardiovascular Disease
Elarofiban (RWJ-53308) is a nonpeptide, orally active antagonist for *fibrinogen receptor* α_IIbβ₃ (GPIIb/IIIa), with an IC₅₀** of 0.15 nM. Elarofiban has the potential for platelet mediated thrombotic disorders research .

HY-111348

Lamifiban Ro 44-9883	Integrin	Cardiovascular Disease
Lamifiban is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban is promising for research of acute coronary syndromes .

HY-163101

CP-96021	Platelet-activating Factor Receptor (PAFR) Leukotriene Receptor	Inflammation/Immunology
CP-96021 is an orally active dual leukotriene D4 (LTD4) and platelet activating factor (PAF) *receptor* antagonist, featuring a guinea pig LTD4 receptor K_i of 34 nM and a rabbit PAF receptor K_i of 37 nM. CP-96021 blocks ligand binding to its target receptors, inhibits ligand-induced bronchoconstriction, and inhibits antigen-triggered airway obstructive effects. CP-96021 can be used for the research of asthma .

HY-111348A

Lamifiban TFA	Integrin	Cardiovascular Disease
Lamifiban TFA is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban TFA in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban TFA is promising for research of acute coronary syndromes .

HY-10315A

Elarofiban diTFA	Integrin	Cardiovascular Disease
Elarofiban diTFA is the salt form of Elarofiban (HY-10315) with two TFA. Elarofiban diTFA is a nonpeptide, orally active antagonist for *fibrinogen receptor* α_IIbβ₃ (GPIIb/IIIa), with an IC₅₀** of 0.15 nM. Elarofiban diTFA has the potential for platelet mediated thrombotic disorders research .

HY-179246

CXT29	COX Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
CXT29 is an orally active COX-2 inhibitor and a thromboxane A₂ receptor (TP) antagonist. CXT29 exhibits COX inhibitory activity and selectivity, with IC₅₀ values of 13 and 722 nM for COX-2 and COX-1 respectively. CXT29 inhibits platelet aggregation induced by U-46619 (HY-108566) (a TP agonist), with an IC₅₀ of 96 nM. CXT29 effectively inhibits the production of TXB₂ and PGE₂, significantly reducing platelet aggregation and inflammatory pain in mice. CXT29 can be used for research on inflammatory pain and cardiovascular diseases .

HY-133003

L662,025	Platelet-activating Factor Receptor (PAFR)	Metabolic Disease Inflammation/Immunology
L662,025 is a specific, photolabile and irreversible **Platelet-activating factor (PAF-receptor) antagonist, with IC₅₀** values of 5.6 μM (platelet aggregation) and 1 μM (receptor binding), respectively .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-15371

Forskolin Maximum Cited Publications 210 Publications Verification Coleonol; Colforsin; HL 362	Classification of Application Fields Terpenoids Labiatae Metabolic Disease Diterpenoids Plants Inflammation/Immunology Disease Research Fields Endocrinology Pueraria montana (Lour.) Merr. Source Classification	Organoid Adenylate Cyclase FXR Autophagy PKC
Forskolin (Coleonol) is a potent adenylate cyclase activator with an IC₅₀ of 41 nM and an EC₅₀ of 0.5 μM for type I adenylyl cyclase . Forskolin is also an inducer of intracellular cAMP formation . Forskolin induces differentiation of various cell types and activates *pregnane X receptor* (PXR) and FXR** . Forskolin exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin also induces autophagy .

HY-B0228

Adenosine 15+ Cited Publications Adenine riboside; D-Adenosine	Structural Classification Natural Products Microorganisms Classification of Application Fields Marine natural products Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Environmental Pollutants Autophagy Nucleoside Antimetabolite/Analog Endogenous Metabolite Apoptosis
Adenosine (Adenine riboside), a ubiquitous and BBB-permeable endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation .

HY-B0131

Prostaglandin E1 20+ Cited Publications Alprostadil; PGE1	Cardiovascular Disease Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification	Prostaglandin Receptor Endogenous Metabolite
Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with K_is of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases .

HY-108635

C16-PAF 35+ Cited Publications PAF (C16)	Natural Products Human Gut Microbiota Metabolites Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	p38 MAPK MEK ERK Endogenous Metabolite
C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability .

HY-N0660

Jujuboside B	Cardiovascular Disease Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Plants Disease Research Fields Source Classification	Apoptosis PARP Caspase AMPK Autophagy VEGFR Keap1-Nrf2 STING 11β-HSD Ferroptosis PI3K Akt p38 MAPK ERK
Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM_2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes .

HY-B0228R

Adenosine (Standard) Adenine riboside (Standard); D-Adenosine (Standard)	Structural Classification Natural Products Microorganisms Endogenous metabolite Source Classification	Reference Standards Nucleoside Antimetabolite/Analog Autophagy Apoptosis Endogenous Metabolite
Adenosine (Standard) is the analytical standard of Adenosine. This product is intended for research and analytical applications. Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation .

HY-15371R

Forskolin (Standard) Coleonol (Standard); Colforsin (Standard); HL 362 (Standard)	Structural Classification Terpenoids Labiatae Diterpenoids Plants Pueraria montana (Lour.) Merr. Source Classification	Organoid Reference Standards Adenylate Cyclase FXR Autophagy PKC
Forskolin (Standard) is the analytical standard of Forskolin. This product is intended for research and analytical applications. Forskolin (Coleonol) is a potent adenylate cyclase activator with an IC₅₀ of 41 nM and an EC₅₀ of 0.5 μM for type I adenylyl cyclase . Forskolin is also an inducer of intracellular cAMP formation . Forskolin induces differentiation of various cell types and activates pregnane X receptor (PXR) and FXR . Forskolin exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin also induces autophagy .

HY-N0910

Notoginsenoside Ft1 1 Publications Verification	Triterpenes Structural Classification Panax notoginseng (Burkill) F. H. Chen ex C. H. Chow Classification of Application Fields Terpenoids Other Diseases Plants Disease Research Fields Araliaceae Source Classification	PI3K mTOR Akt Apoptosis p38 MAPK ERK Transmembrane Glycoprotein Glutathione Reductase (GR) Estrogen Receptor/ERR Calcium Channel Ferroptosis G protein-coupled Bile Acid Receptor 1 FXR
Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 ⁺ T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca ²⁺ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y₁₂ receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance .

HY-141581

Lyso-PAF C-18	Cardiovascular Disease Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	Platelet-activating Factor Receptor (PAFR) Endogenous Metabolite
Lyso-PAF C-18 is an intermediate for the synthesis of C18-PAF (HY-130345). It has an easily substituted "Lyso-PAF" structure and is easy to purify and has high yield. C18-PAF is a ligand for platelet-activating factor and PAF G protein-coupled receptor (PAFR) and has renovasodilator properties and antihypertensive lipid properties .

HY-N4267

Yangambin	Cardiovascular Disease Structural Classification other families Classification of Application Fields Lignans Phenylpropanoids Plants Disease Research Fields Source Classification	Calcium Channel Platelet-activating Factor Receptor (PAFR) UGT Leukotriene Receptor TNF Receptor PGE synthase Interleukin Related
Yangambin is a PAF receptor antagonist and UGT1A1/UGT1A3 inhibitor, with an IC₅₀ of 29.7 μM and a K_i of 17.1 μM against human UGT1A1, and an IC₅₀ of 56.5 μM and a K_i of 66.8 μM against human UGT1A3. Yangambin blocks PAF-mediated responses, inhibits LTB₄-mediated neutrophil infiltration, and suppresses inflammatory events and anaphylactic contraction. Yangambin acts as a central nervous system inhibitor to reduce spontaneous activity, and also exhibits analgesic, anticonvulsant, antileishmanial, vasodilatory and hypotensive effects. Yangambin blocks voltage-gated Ca ²⁺ channels, reduces the production of NO, TNF-α, IL-6 and PGE2 in cells, increases the production of IL-10, and exerts a protective effect against cardiovascular injury. Yangambin can be used in research related to allergies, cutaneous leishmaniasis, central nervous system diseases and cardiovascular diseases .

HY-N7740

Adenosine 2',5'-diphosphate sodium	Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Endogenous metabolite Disease Research Fields Source Classification	P2Y Receptor Endogenous Metabolite
Adenosine 2',5'-diphosphate sodium is a competitive P2Y1 antagonist. Adenosine 2',5'-diphosphate sodium exhibits non-selective antagonism at recombinant and human platelet P2X1 receptors .

HY-N12995

α-Bulnesene	Entada phaseoloides (L.) Merr. Terpenoids Labiatae Sesquiterpenes Plants Source Classification	Platelet-activating Factor Receptor (PAFR)
α-Bulnesene is a novel PAF receptor antagonist with the IC₅₀ of 17.62 μM. α-Bulnesene can be isolated from Pogostemon cablin. α-Bulnesene shows inhibitory effect on platelet-activating factor and arachidonic acid induced rabbit platelet aggregation .

HY-N3643

Cryptomeridiol	Acanthaceae Stachys riederi Cham. Plants Source Classification	Platelet-activating Factor Receptor (PAFR)
Cryptomeridiol is a **platelet-activating factor (PAF) receptor** binding inhibitor. Cryptomeridiol has melanogenesis inhibitory activity in the α-MSH (HY-P0252)-stimulated B16 melanoma cells .

HY-B0131R

Prostaglandin E1 (Standard) Alprostadil(Standard); PGE1 (Standard)	Cardiovascular Disease Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification	Reference Standards Prostaglandin Receptor Endogenous Metabolite
Prostaglandin E1 (Standard) is the analytical standard of Prostaglandin E1. This product is intended for research and analytical applications. Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases .

HY-167686

Variabilin Homopisatin	Structural Classification Natural Products Plants Dalbergia variabilis Fabaceae Source Classification	Integrin
Variabilin (Homopisatin) is a potent RGD-containing antagonist of glycoprotein IIb-IIIa and platelet aggregation inhibitor from the hard tick Dermacentor variabilis. Variabilin potently inhibits platelet aggregation induced by the platelet agonists ADP, collagen, and thrombin receptor peptide SFLLRNP. Variabilin also blocks platelet adhesion to immobilized Fg. In addition, Variabilin inhibits binding of purified human GPIIb-IIIa to immobilized Fg .

HY-121377

Epiyangambin	Tephrosia deflexa Baker Labiatae Lignans Phenylpropanoids Plants Source Classification	Platelet-activating Factor Receptor (PAFR)
Epiyangambin is a competitive platelet activating factor receptor (PAF) antagonist that dose-dependently inhibits PAF-induced platelet aggregation. Epiyangambin also inhibits the growth of human colon cancer cells (SW480 cells) .

HY-N3436

Kadsurin A	Lignans Piperaceae Phenylpropanoids Plants Piper kadsura (Choisy) Ohwi Source Classification	Platelet-activating Factor Receptor (PAFR)
Kadsurin A is a new lignan can be isolated from Piper futokadsura. Kadsurin A is a platelet activating factor (PAF) receptor antagonist that weakly inhibits the binding of PAF to its receptor .

HY-W007888R

2-Hydroxy-4-methylbenzaldehyde (Standard)	Structural Classification Monophenols Ketones, Aldehydes, Acids Phenols Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Prostaglandin E1 (Standard) is the analytical standard of Prostaglandin E1. This product is intended for research and analytical applications. Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases .

HY-108635R

C16-PAF (Standard) PAF (C16) (Standard)	Structural Classification Natural Products Human Gut Microbiota Metabolites Endogenous metabolite Source Classification	p38 MAPK MEK ERK Endogenous Metabolite Reference Standards
C16-PAF (Standard) is the analytical standard of C16-PAF. This product is intended for research and analytical applications. C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability .

HY-N19251

Sulfobacin B	Structural Classification Natural Products Microorganisms Source Classification	Integrin
Sulfobacin B is a competitive von Willebrand factor receptor GPIb/IX inhibitor with an IC₅₀ of 2.2 μM. Sulfobacin B inhibits binding of von Willebrand factor to GPIb/IX in a competitive manner. Sulfobacin B can be used for the research of thrombosis .

HY-N18260

Desmodilactone	Structural Classification Grona styracifolia (Osbeck) H. Ohashi & K. Ohashi Ketones, Aldehydes, Acids Plants Fabaceae Source Classification	P2Y Receptor
Desmodilactone is a P2Y1R allosteric antagonist. Desmodilactone can be used for the research of thrombosis .

HY-N0660R

Jujuboside B (Standard)	Triterpenes Structural Classification other families Terpenoids Plants Source Classification	Reference Standards ERK p38 MAPK Akt PI3K 11β-HSD STING VEGFR Ferroptosis Autophagy Apoptosis Keap1-Nrf2 Caspase PARP AMPK
Jujuboside B (Standard) is the analytical standard of Jujuboside B. This product is intended for research and analytical applications. Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM_2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes.

Cat. No.	Product Name	Chemical Structure

HY-B0590S

Tetrabenazine-d6

Tetrabenazine-d₆ (Deutetrabenazine) is a deuterium-labled Tetrabenazine (HY-B0590). Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-B0228S1

Adenosine-13C5
Adenosine- ¹³C₅ is the ¹³C labeled Adenosine . Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation .

HY-B0228S11

Adenosine-15N5

Adenosine- ¹⁵N₅ (Adenine riboside- ¹⁵N₅; D-Adenosine- ¹⁵N₅) is the ¹⁵N labled Adenosine (HY-B0228). Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation .

HY-B0228S13

Adenosine-13C10

Adenosine- ¹³C₁₀ (Adenine riboside- ¹³C₁₀; D-Adenosine- ¹³C₁₀) is ¹³C-labeled Adenosine (HY-B0228). Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation.

HY-B0228S9

Adenosine-13C10,15N5

Adenosine- ¹³C₁₀, ¹⁵N₅ is the ¹³C and ¹⁵N labeled Adenosine (HY-B0228) . Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation .

HY-B0228S

Adenosine-d1
Adenosine-d is the deuterium labeled Adenosine. Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation .

HY-15284S2

Prasugrel-d4
Prasugrel-d₄ is the deuterium labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-10064S

Ticagrelor-d7
Ticagrelor-d₇ is the deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation .

HY-B0228S12

Adenosine-d13

Adenosine-d₁₃ (Adenine riboside-d₁₃; D-Adenosine-d₁₃) is deuterium labeled Adenosine (HY-B0228). Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation.

HY-15306S

Eltrombopag-13C4

1 Publications Verification

Eltrombopag- ¹³C₄ (SB-497115- ¹³C₄) is ^{13 sup>C-labeled Z-Eltrombopag. Z-Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells .}

HY-13463BS

Avatrombopag-d8 hydrochloride

Avatrombopag-d₈ (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC₅₀=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-15284S1

Prasugrel-d3
Prasugrel-d₃ is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284S

Prasugrel-d5
Prasugrel-d₅ is deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284S3

Prasugrel-13C6
Prasugrel-13C6 is a deuterated labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-107867S1

(Rac)-Clopidogrel hydrogen-d9 sulfate

(Rac)-Clopidogrel hydrogen-d₉ sulfate is the deuterium labeled (±)-Clopidogrel (bisulfate) (HY-107867). (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .

HY-107867S2

Clopidogrel-13C,d3 sulfate

Clopidogrel- ¹³C,d₃ sulfate is the deuterium and ¹³C-labeled (±)-Clopidogrel (bisulfate) (HY-107867). (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .

HY-17000S

Tolvaptan-d7
Tolvaptan-d₇ is the deuterium labeled Tolvaptan. Tolvaptan is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC₅₀ of 1.28μM for the inhibition of AVP-induced platelet aggregation .

HY-10064S1

Ticagrelor-d4
Ticagrelor-d₄ (AZD6140-d₄) is deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.

HY-10119S

Vorapaxar-d5
Vorapaxar-d₅ is deuterated labeled Vorapaxar (HY-10119). Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor *protease-activated receptor* (PAR-1) antagonist (K_i*=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet* aggregation in a dose-dependent manner .

HY-B2158S

Chlorotrianisene-d9
Chlorotrianisene-d₉ is the deuterium labeled Chlorotrianisene. Chlorotrianisene is a long-acting non-steroidal estrogen and an orally active estrogen receptor modulator. Chlorotrianisene exhibits antiestrogenic activity. Chlorotrianisene potently inhibits the enzyme COX-1 and inhibits platelet aggregation in whole blood .

HY-W779021

Adenosine-15N
Adenosine- ¹⁵N (Adenine riboside- ¹⁵N) is ¹⁵N labeled Adenosine. Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation .

HY-108634S

Apafant-d8
Apafant-d₈ is the deuterium labeled Apafant. Apafant (WEB 2086) is a potent platelet-activating factor (PAF) antagonist, inhibits PAF binding to human PAF receptors with a K_iof 9.9 nM. Apafant increases the gene expression of PAF-r, α-globin, β-globin, decreases the c-myb gene expression. Apafant shows a protective effect on alkyl-PAF-mediated lethalit .

HY-130304S

8-Isoprostaglandin E2-d4

8-Isoprostaglandin E2-d₄ (iPE2-III-d₄) is deuterium labeled 8-Isoprostaglandin E2. 8-Isoprostaglandin E2 (iPE2-III) is a member of the isoprostane class of prostanoids. 8-Isoprostaglandin E2 acts at the receptor for thromboxane A₂ (the TP) in vivo to induce vasoconstriction and platelet aggregation. 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway .

HY-B0131S

Prostaglandin E1-d4

Prostaglandin E1-d₄ is the deuterium labeled Prostaglandin E1. Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with K_is of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases .

HY-W713365

Eltrombopag-d3

Eltrombopag-d₃ (SB-497115-d₃) is deuterium labeled Eltrombopag. Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .

HY-B0590S3

Tetrabenazine-d7

Tetrabenazine-d₇ (TBZ-d₇-d₇) is deuterium labeled Tetrabenazine (HY-B0590). Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-15283AS1

(±)-Clopidogrel-d4

(±)-Clopidogrel-d₄ ((±)-Clopidogrelum-d₄) is the deuterium labeled (±)-Clopidogrel (HY-107867). (±)-Clopidogrel is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel has anti-inflammatory effects .

Targets Recommended: Platelet-activating Factor Receptor (PAFR) PDGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148748G

Butyzamide	JAK STAT p38 MAPK	Cardiovascular Disease
Butyzamide (GMP) is Butyzamide (HY-148748) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of platelets in mouse xenotransplantation assay .

HY-15371G

Forskolin Coleonol; Colforsin; HL 362	Adenylate Cyclase FXR Autophagy PKC	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Forskolin (Coleonol) (GMP) is a potent adenylate cyclase activator with an IC₅₀ of 41 nM and an EC₅₀ of 0.5 μM for type I adenylyl cyclase . Forskolin (GMP) is also an inducer of intracellular cAMP formation . Forskolin (GMP) induces differentiation of various cell types and activates *pregnane X receptor* (PXR) and FXR** . Forskolin (GMP) exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin (GMP) also induces autophagy .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks